Ruxolitinib (Jakafi, Opzelura)
Targeted Therapy · Approved since 2011
Description
Ruxolitinib is a selective Janus kinase (JAK) inhibitor that blocks JAK1 and JAK2 signaling pathways. While approved for certain blood cancers and inflammatory conditions, ruxolitinib is being explored in colorectal cancer through combination approaches with other targeted agents. In CRC, it is primarily tested alongside MEK inhibitors like trametinib to target multiple oncogenic pathways simultaneously.
Mechanism of Action
Ruxolitinib selectively inhibits JAK1 and JAK2 kinases, which are critical components of the JAK-STAT signaling pathway involved in cell proliferation, survival, and immune responses. By blocking these kinases, ruxolitinib disrupts cytokine signaling that can promote tumor growth and inflammation in the tumor microenvironment.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Jakafi, Opzelura |
| Category | Targeted Therapy |
 Status | Off-label |
 EMA Status | EMA Approved |
 Spain Access | Hospital use off-label in CRC |
| Administration | Oral |
| Year Approved | 2011 |
| Clinical Trials | 4 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.